{"id":26116,"date":"2024-07-11T12:31:24","date_gmt":"2024-07-11T10:31:24","guid":{"rendered":"https:\/\/idibell.cat\/?p=26116"},"modified":"2024-07-11T12:31:24","modified_gmt":"2024-07-11T10:31:24","slug":"lhospital-de-bellvitge-incorpora-la-intelligencia-artificial-per-veu-al-seguiment-dels-pacients-amb-asma-greu","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2024\/07\/lhospital-de-bellvitge-incorpora-la-intelligencia-artificial-per-veu-al-seguiment-dels-pacients-amb-asma-greu\/","title":{"rendered":"L\u2019Hospital de Bellvitge incorpora la intel\u00b7lig\u00e8ncia artificial per veu al seguiment dels pacients amb asma greu"},"content":{"rendered":"

Dins d\u2019un projecte de recerca d\u2019un any de durada de l\u2019IDIBELL i l\u2019Hospital Universitari de Bellvitge (HUB), recolzat per una donaci\u00f3 de suport no condicionat de GlaxoSmithKline (GSK), aquest mes de juliol s\u2019ha comen\u00e7at a utilitzar la intel\u00b7lig\u00e8ncia artificial per veu per al seguiment dels pacients amb asma greu.<\/span>\u00a0<\/span><\/p>\n

Aquest projecte \u00e9s una de les l\u00ednies de treball del Grup de Recerca en Pneumologia de l\u2019IDIBELL i l\u2019HUB enfocada a la malaltia respirat\u00f2ria cr\u00f2nica d\u2019alta complexitat (MAC-Res). <\/span>El projecte es recolza en l\u2019\u00fas de l\u2019assistent virtual Lola, desenvolupat per l\u2019empresa espanyola Tucuvi. Aquest assistent s\u2019ha comen\u00e7at a utilitzar en els darrers anys en diferents projectes de seguiment de malalties, per\u00f2 aquesta \u00e9s la primera vegada a Espanya que s\u2019aplica l\u2019asma greu.<\/span>\u00a0<\/span><\/p>\n

L\u2019assistent t\u00e9 una veu d\u2019aparen\u00e7a humana que telefona autom\u00e0ticament el pacient i conversa amb ell fent-li unes preguntes sobre el seu estat, el compliment de la medicaci\u00f3, o la comprovaci\u00f3 de diversos par\u00e0metres. El sistema transforma les respostes del pacient en un informe que arriba immediatament als professionals de l\u2019Hospital a trav\u00e9s d\u2019un aplicatiu web. Si l\u2019informe inclou alguna dada preocupant, el sistema emet una alerta. El q\u00fcestionari als pacients ha estat dissenyat pels especialistes en asma de l\u2019IDIBELL i l\u2019HUB i va comptar amb l\u2019opini\u00f3 d\u2019un grup de pacients i ciutadans no sanitaris, i el control i revisi\u00f3 de la informaci\u00f3 que proporciona el sistema va a c\u00e0rrec de professionals d\u2019infermeria expert, qui s\u00f3n el referent de les comunicacions telem\u00e0tiques dels pacients amb l\u2019hospital. En aquest sentit, la Direcci\u00f3 d’Infermeria de l\u2019HUB ha facilitat el recursos necessaris per a la implementaci\u00f3 del programa.<\/span>\u00a0<\/span><\/p>\n

El projecte inclour\u00e0 un total de 250 pacients amb l\u2019objectiu d\u2019investigar si aquest seguiment m\u00e9s intens automatitzat aconsegueix detectar abans les descompensacions i millora l\u2019evoluci\u00f3 dels malalts. Tots els participants reben informaci\u00f3 pr\u00e8via sobre el projecte i, en principi, l\u2019assistent els telefona un cop al mes, si b\u00e9 aquesta periodicitat pot augmentar en funci\u00f3 de l\u2019estat cada pacient. Fins ara, pr\u00e0cticament el 100% de les trucades automatitzades han estat ateses i contestades correctament.<\/span>\u00a0<\/span><\/p>\n

La Dra. Mariana Mu\u00f1oz, investigadora principal del grup de recerca en Pneumologia de l\u2019IDIBELL i coordinadora de la Unitat Funcional d\u2019Asma de l\u2019HUB, recorda que fa uns mesos ja van ser pioners en telemedicina amb la <\/span>posada en marxa d\u2019un aplicatiu m\u00f2bil per al control de la malaltia<\/span><\/a>. Ara, destaca que aquesta nova prestaci\u00f3 \u201cencara posa m\u00e9s facilitats, ja que no requereix instal\u00b7lar ni utilitzar cap aplicaci\u00f3, nom\u00e9s contestar una trucada de cinc o sis minuts\u201d. A aix\u00f2 s\u2019hi afegeix que, en el cas de l\u2019asma, \u201cestem en un context global de creixement de la malaltia per l\u2019envelliment de la poblaci\u00f3, l\u2019augment de la cronicitat i problemes com ara la contaminaci\u00f3 i el canvi clim\u00e0tic, cosa que requerir\u00e0 el suport de totes les solucions possibles\u201d.<\/span>\u00a0<\/span><\/p>\n

 <\/p>\n

L\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l\u2019Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l\u2019Institut Catal\u00e0 de la Salut, l\u2019Institut Catal\u00e0 d\u2019Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n

L\u2019IDIBELL \u00e9s membre del Campus d\u2019Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L\u2019any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

\u00c9s la primera vegada que s\u2019aplica aquesta tecnologia a l\u2019asma a Espanya. Fa uns mesos, aquest grup de l\u2019IDIBELL i l\u2019HUB ja va posar en marxa un aplicatiu m\u00f2bil pel seguiment de la malaltia.<\/p>\n","protected":false},"author":8,"featured_media":26117,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[334,466,467],"tags":[],"class_list":["post-26116","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicina-translacional","category-p-de-malalties-cardiovasculars-respiratories-sistemiques-i-denvelliment-cellular","category-pneumologia"],"publishpress_future_action":{"enabled":false,"date":"2024-11-29 09:13:27","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=26116"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26116\/revisions"}],"predecessor-version":[{"id":26119,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26116\/revisions\/26119"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/26117"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=26116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=26116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=26116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}